A5060067760- Neuroendocrine Tumor Research Advances
- Thyroid Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Neuroblastoma Research and Treatments
- Parathyroid Disorders and Treatments
- Thyroid and Parathyroid Surgery
- Cancer-related Molecular Pathways
- BRCA gene mutations in cancer
- Nutrition, Genetics, and Disease
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Genetic Syndromes and Imprinting
- Adrenal and Paraganglionic Tumors
- Cancer Diagnosis and Treatment
- Hippo pathway signaling and YAP/TAZ
- Gastrointestinal Tumor Research and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer Mechanisms and Therapy
- Pituitary Gland Disorders and Treatments
- Heparin-Induced Thrombocytopenia and Thrombosis
- Cancer Genomics and Diagnostics
- Venous Thromboembolism Diagnosis and Management
- Sarcoma Diagnosis and Treatment
- Glioma Diagnosis and Treatment
- Renal cell carcinoma treatment
Memorial Sloan Kettering Cancer Center
2016-2025
Kettering University
2018-2025
Cornell University
2021
Policlinico S.Orsola-Malpighi
2020
University of Bologna
2020
University of Iowa Hospitals and Clinics
2020
Istituto Ortopedico Rizzoli
2020
Queen Elizabeth Hospital Birmingham
2020
Icahn School of Medicine at Mount Sinai
2019
Molecular Oncology (United States)
2017
Active surveillance of low-risk papillary thyroid cancer (PTC) is now an accepted alternative to immediate surgery, but experience with this approach outside Japan limited. The kinetics (probability, rate, and magnitude) PTC tumor growth under active have not been well defined.To describe the during surveillance.Cohort study 291 patients undergoing for (intrathyroidal tumors ≤1.5 cm) serial measurements via ultrasonography at a tertiary referral center in United States.Active...
Most well-differentiated neuroendocrine tumors (WD-NET) of the enteropancreatic system are low-intermediate grade (G1, G2). Elevated proliferation demonstrated by either a brisk mitotic rate (>20/10 high power fields) or Ki-67 index (>20%) defines group aggressive neoplasms designated as high-grade (G3) carcinoma (NEC). High-grade NEC is equated with poorly differentiated (PD-NEC) and associated dismal outcome. Progression WD-NETs to neoplasm very rarely occurs their clinicopathologic...
Abstract The commonly mutated genes in pancreatic neuroendocrine tumors (PanNETs) are ATRX , DAXX and MEN1 . We genotyped 64 PanNETs found 58% carry mutations (A-D-M mutant PanNETs) this correlates with a worse clinical outcome than carrying the wild-type alleles of all three WT PanNETs). performed RNA sequencing DNA-methylation analysis to reveal two distinct subgroups one consisting entirely A-D-M PanNETs. Two differentiating from were high ARX low PDX1 gene expression promoter...
Adrenocortical carcinomas (ACC) are rare and aggressive malignancies with limited treatment options. This study was undertaken to evaluate the immunogenicity of ACC.Patients advanced ACC were enrolled in a phase II clinical activity pembrolizumab 200 mg every 3 weeks, without restriction on prior therapy. The primary end point objective response rate. Efficacy correlated tumor programmed death-ligand 1 expression, microsatellite-high and/or mismatch repair deficient (MSI-H/MMR-D) status,...
Abstract The genetic, biologic, and clinical heterogeneity of sarcomas poses a challenge for the identification therapeutic targets, research, advancing patient care. Because there are > 100 sarcoma subtypes, in-depth genetic studies have focused on one or few subtypes. Herein, we report comparative analysis 2,138 representing 45 pathological entities. This cohort is prospectively analyzed using targeted sequencing to characterize subtype-specific somatic alterations in targetable...
Abstract Ch22q LOH is preferentially associated with RAS mutations in papillary and poorly differentiated thyroid cancer (PDTC). The 22q tumor suppressor NF2, encoding merlin, implicated this interaction because of its frequent loss function human cell lines. Nf2 deletion or Hras mutation insufficient for transformation, whereas their combined disruption leads to murine PDTC increased MAPK signaling. Merlin induces signaling part through inactivation Hippo, which activates a YAP–TEAD...
Purpose: Patients with anaplastic thyroid cancer (ATC) have a very high death rate. In contrast, deaths from non-anaplastic (NAT) are much less common. The genetic alterations in fatal NAT cancers not been reported.Experimental Design: We performed next-generation sequencing of 410 genes 57 primary cancers. Results were compared Cancer Genome Atlas study (TCGA study) papillary (PTCs) and to the genomic changes reported ATC.Results: There was prevalence TERT promoter mutations, comparable...
Emerging data suggest that not all grade 3 (G3) pancreatic neuroendocrine neoplasms (panNENs) behave the same; tumor differentiation may predict outcome.Patients with G3 panNENs treated at our institution between 1999 and 2014 were identified. Demographics, response to therapy, overall survival determined.Forty-five patients identified, 16 well differentiated tumors (WD-panNETs) 29 poorly carcinomas (PDNEC). Median in WD-panNET was 52.2 months (95% confidence interval, 19.3-86.9 months)...
Medullary thyroid carcinoma (MTC) is an aggressive neuroendocrine tumor (NET) arising from the calcitonin-producing C cells. Unlike other NETs, there no widely accepted pathologic grading scheme. In 2020, two groups separately developed slightly different schemes (the Memorial Sloan Kettering Cancer Center and Sydney grade) on basis of proliferative activity (mitotic index and/or Ki67 index) necrosis. Building this work, we sought to unify validate internationally scheme for MTC.Tumor tissue...
Background: The change in size of the papillary thyroid cancer (PTC) nodule during active surveillance has traditionally been characterized as either stable, increasing, or decreasing based on changes maximal tumor diameter volume. More recently, it observed that observation are more complex with volume kinetic patterns can be stable (Pattern I), early increase II), later III), followed by stability IV), an V), a decrease VI). Methods: frequency, time course, and clinical correlates these...
RBM10 modulates transcriptome-wide cassette exon splicing. Loss-of-function mutations are enriched in thyroid cancers with distant metastases. Analysis of transcriptomes and genes mis-spliced by loss showed pro-migratory RHO/RAC signaling signatures. increases cell velocity. Cytoskeletal ECM transcripts subject to inclusion events included vinculin (VCL), tenascin C (TNC), CD44. Knockdown the VCL transcript RBM10-null cells reduced velocity, whereas knockdown TNC CD44 isoforms invasiveness....
Of the three RAS oncoproteins, only HRAS is delocalized and inactivated by farnesyltransferase inhibitors (FTI), an approach yet to be exploited clinically. In this study, we treat mice bearing Hras-driven poorly differentiated anaplastic thyroid cancers (Tpo-Cre/HrasG12V/p53flox/flox ) with FTI tipifarnib. Treatment caused sustained tumor regression increased survival; however, early late resistance was observed. Adaptive reactivation of RAS-MAPK signaling abrogated in vitro selective RTK...
We assessed the usefulness of real-time molecular profiling through next-generation sequencing (NGS) in predicting tumor biology advanced pancreatic neuroendocrine tumors (panNETs) and characterizing genomic evolution.Patients with metastatic panNETs were recruited routine clinical practice setting (between May 2014 March 2017) for prospective NGS their as well germline analysis using Memorial Sloan Kettering-Integrated Mutation Profiling Actionable Cancer Targets (MSK-IMPACT) platform. When...
Lung carcinoids (LC) are rare and slow growing primary lung neuroendocrine tumors. We performed targeted exome sequencing, mRNA DNA methylation array analysis on macro-dissected LCs. Recurrent mutations were enriched for genes involved in covalent histone modification/chromatin remodeling (34.5%; MEN1, ARID1A, KMT2C, KMT2A) as well repair (17.2%) pathways. Unsupervised clustering principle component gene expression profiles showed three robust molecular subtypes (LC1, LC2, LC3) with distinct...
Medullary thyroid carcinoma (MTC) is a rare nonfollicular cell-derived tumor. A robust grading system may help better stratify patients at risk for recurrence and death from disease. In total, 144 MTC between 1988 2018 were subjected to detailed histopathologic evaluation. Clinical pathologic data correlated with disease specific survival (DSS), local free (LRFS) distant metastasis (DMFS). Median age was 53 years (range: 3-88). tumor size 1.8 cm 0.2-11). Lymph node metastases present in 84...
High-grade neuroendocrine neoplasms are a rare disease entity and account for approximately 10% of all neoplasms. Because their rarity, there is an overall lack prospectively collected data available to advise practitioners as how best manage these patients. As result, practices largely based on expert opinion. Recently, distinction was made between well-differentiated high-grade (G3) tumors poorly differentiated carcinomas, with this, pathologic details, appropriate imaging treatment have...
Purpose: The prognostic importance of RET and RAS mutations their relationship to clinicopathologic parameters outcomes in medullary thyroid carcinoma (MTC) need be clarified.
Background and Objectives Patients with metastatic RCC can undergo metastasectomy to improve survival time. Our goal was provide compare characteristics oncological outcomes of patients who underwent complete at a single organ site. Methods A total 138 were identified as undergoing site including adrenal, lung, liver, pancreas, or thyroid. Competing risk regression analysis used assess RFS CSS adjusting for several covariates. Results In this highly selected cohort, 27% 84% 5 years following...